The nation of Zimbabwe has rejected a significant US health deal worth $367m (272 million pounds) spanning five years due to the United States' insistence on confidential biological samples.
This move came to light after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
An official spokesperson later explained that the United States was requesting genetic material for scientific study and commercial gain but was not willing to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for further dialogue to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can proceed.
Broader Context
This rejection comes after a comparable case in Kenya, where a high court blocked a similar deal with the US after concerns were filed about the security of citizens' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government agreements to enhance transparency and accountability.
According to statements, 16 African countries have so far agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for medical research with no assurance that the final treatments would be available to our citizens if a new health crisis arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one health agreements were upending frameworks previously established via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage future global health emergencies.
"This framework is designed to ensure that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation could be arranged in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body said it acknowledged the government's concerns, but recommended that talks should continue since much of the country's HIV programmes depended on foreign aid.
"Where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it added.
The halted deal highlights the ongoing tensions between receiving vital international aid and safeguarding local interests in an ever more data-driven world.